Present and future of FDG-PET/CT in ovarian cancer.
Integrated FDG-PET/CT has been used successfully for the diagnosis, staging, restaging, therapy monitoring and prognostic prediction of ovarian cancer as well as various other malignant tumors. Compared with conventional PET/non-contrast CT images, combined PET/contrast-enhanced CT images with intravenous iodine contrast medium and sufficient radiation dose may contribute to a more accurate diagnosis with higher confidence. In the future, tracers other than FDG and integrated PET/MRI will be realized. We herein review the place and role of FDG-PET/CT in the management of ovarian cancer, discussing its usefulness and limitations in the imaging of these patients.
Department of PET Diagnosis, Institute of Biomedical Research and Innovation, 2-2 Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan. kitajima@med.kobe-u.ac.Jp
Kazuhiro
K
Kitajima
Koji
K
Murakami
Setsu
S
Sakamoto
Yasushi
Y
Kaji
Kazuro
K
Sugimura
D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D049268:Positron-Emission Tomography / Q000379:methods* / Q000639:trends*; D014057:Tomography, X-Ray Computed / Q000379:methods* / Q000639:trends*; D016896:Treatment Outcome
D019788:Fluorodeoxyglucose F18